Altimmune (NASDAQ:ALT) Posts Earnings Results, Beats Estimates By $0.01 EPS

Altimmune (NASDAQ:ALT) posted its quarterly earnings data on Thursday. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01, Zacks reports. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%.

Altimmune Stock Performance

NASDAQ:ALT traded up $0.48 during trading hours on Thursday, reaching $6.42. The stock had a trading volume of 4,397,467 shares, compared to its average volume of 2,211,671. Altimmune has a 52 week low of $5.28 and a 52 week high of $14.84. The company has a 50 day moving average price of $6.92 and a two-hundred day moving average price of $7.19. The stock has a market capitalization of $456.59 million, a PE ratio of -4.14 and a beta of 0.19.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Stifel Nicolaus assumed coverage on Altimmune in a research report on Wednesday, January 8th. They set a “buy” rating and a $18.00 price objective on the stock. UBS Group initiated coverage on Altimmune in a report on Tuesday, November 12th. They issued a “buy” rating and a $26.00 price target on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Altimmune in a report on Wednesday, February 5th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $20.83.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.